News | October 19, 2008

CMS to Consider Expanding Reimbursement for PET

October 20, 2008 — In response to a successful data collection effort by the National Oncologic PET Registry (NOPR) showing that positron emission tomography (PET) scans help save the lives of thousands of cancer patients annually, the Centers for Medicare and Medicaid Services (CMS) is weighing an expansion of coverage of PET for all types of cancer.

In concert with other nonprofit medical associations, SNM has worked closely with CMS over the past three years to increase access to these medically essential molecular imaging procedures used for the diagnosis, staging and restaging of cancer. Molecular imaging provides a rich portrait of exactly what is going on in a patient's body, offering a wealth of useful information to help shape a treatment plan.

"We believe it essential for patients that CMS adopt a comprehensive reimbursement policy for PET," said SNM President Robert W. Atcher, Ph.D., M.B.A. "We applaud CMS' decision to consider broadening coverage for PET—a vital, state-of-the-art technique that gives physicians critical information for patient care. Molecular imaging techniques, such as PET, can pinpoint the precise location of disease, give us specific information on the metabolic and physiologic status of the disease and enable physicians to target treatment and prevent unnecessary surgery."

NOPR was developed in response to a proposal from CMS to expand coverage for PET—using the radiotracer fluorodeoxyglucose (FDG-PET)—to include cancers and indications not presently eligible for Medicare reimbursement, including cancers of the ovary, uterus, prostate, pancreas, stomach, kidney and bladder. Medicare reimbursement for these cancers was provided if the patient's referring physician and provider submitted data to NOPR to assess the impact of PET on cancer patient management.

Since 2001, CMS has granted year-by-year changes in coverage for a wide spectrum of biologically diverse cancers. Overwhelmingly, evidence collected through NOPR shows that PET has significant advantages for diagnosing, staging and restaging many types of cancer. According to a study published this year in The Journal of Clinical Oncology, PET resulted in a change in management of treatment in more than one-third of cancer patients.

"We believe there is strong empirical evidence to support an omnibus cancer framework that would provide for coverage of PET across all oncologic indications for diagnosis, staging and restaging, including detection of suspected recurrence," said Barry Siegel, M.D., co-chair of the NOPR Working Group. "We propose to continue using NOPR to collect data on the value of PET for this purpose. We will continue to analyze additional data over a longer period."

In response to this positive data, NOPR formally asked CMS to reconsider the current National Coverage decision on oncologic use of FDG-PET and to end the data collection requirements for diagnosis, staging and restaging. CMS issued a Call for Comments for interested parties, including physicians, advocacy groups and imaging societies, to contribute additional information prior to a final reimbursement decision. The comment period ended Oct. 17, and a decision is expected early next year.

NOPR is sponsored by the Academy of Molecular Imaging (AMI), and managed by the American College of Radiology (ACR) and ACR Imaging Network (ACRIN). The registry received input from—and is endorsed by—ACR, the American Society for Clinical Oncology (ASCO) and SNM. The NOPR Working Group was chaired by Bruce Hillner, M.D., of Virginia Commonwealth University and co-chaired by Barry Siegel, M.D., Washington University; R. Edward Coleman, M.D., Duke University; and Anthony Shields, M.D., Wayne State University.

For more information: www.snm.org

Related Content

PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Abnormal Protein Concentrations Found in Brains of Military Personnel With Suspected CTE

Researchers are using the tracer, which is injected into a patient, then seen with a PET scan, to see if it is possible to diagnose chronic traumatic encephalopathy in living patients. In this image, warmer colors indicate a higher concentration of the tracer, which binds to abnormal proteins in the brain. Credit UCLA Health.

News | PET Imaging | August 24, 2018
August 24, 2018 — In a small study of
PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
Novel PET Imaging Method Could Track and Guide Type 1 Diabetes Therapy
News | PET Imaging | August 03, 2018
Researchers have discovered a new nuclear medicine test that could improve care of patients with type 1 diabetes. The...
Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
Overlay Init